MissionIR Articles
-
MissionIRNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Miboko Launch Leveraging ‘Most Reliable Gateway Toward Wider Adoption of Preventative Health Maintenance Practices’
Nemaura Medical (NASDAQ: NMRD) recently announced it would launch Miboko, its new metabolic health program, for employers and insurers. “The Miboko application, a service offering that has been in development over the past 18 months,…
-
Nemaura Medical Inc. (NASDAQ: NMRD) Appoints Technical Healthcare Specialist Dr. Arash Ghadar as COO
NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experience Dr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certification NMRD commercializing…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Marks History Making Milestone with Initial Shipment of CGM Devices
Nemaura Medical (NASDAQ: NMRD) is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible and affordable continuous glucose monitoring (“CGM”) device. “As part of its marketing strategy, NMRD recently completed an initial shipment of…
-
Nemaura Medical Inc. (NASDAQ: NMRD) Commence Rollout of Their Miboko Application; Company Targets Employers & Insurers to Ensure Broad Commercial Distribution
Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently announced the rollout of its Miboko application by targeting insurers and employers In 2019, over $760 billion was…
-
Nemaura Medical Inc. (NASDAQ: NMRD) Firmly Positioned in Growing Diabetes Tech Market With Recent CGM Shipment to UK Licensee
Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS Diabetes is a growing problem in the US. According to CDC, roughly 1 in…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Launches Miboko – a New Metabolic Health Program
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of Miboko for employers and insurers. Miboko is…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at H.C. Wainwright Bioconnect Conference
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Dr. Faz Chowdhury will present a corporate…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Marks True Milestone in Development, Growth
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently completed the initial shipment of its sugarBEAT(R) continuous glucose monitor (“CGM”)…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Solutions to Empower People to Take Charge of Their Health, Well-Being
Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. Since its founding in 2011, Nemaura set out to develop a…
-
Nemaura Medical Inc. (NASDAQ: NMRD) Complete Initial Shipment of sugarBEAT(R) Devices to UK Licensee
Nemaura Medical announced the successful completion of its initial shipment of sugarBEAT(R) continuous glucose monitor devices to its UK licensee The initial shipment, which comprised 5,000 CGM devices and 200,000 sensors, is expected to result…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Positioned to Benefit from Growth in CGM Market
Nemaura Medical (NASDAQ: NMRD) has developed a platform to monitor multiple chemicals in the blood without needles, replacing traditional invasive methods of diagnosis and health care observations. With the global continuous glucose monitoring (“CGM”) devices…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Initial Shipment of CGM Devices to MySugarWatch Licensee
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that it has completed its initial shipment of sugarBEAT(R) continuous…
-
Nemaura Medical Inc. (NASDAQ: NMRD) Helping Diabetic Individuals Safeguard Themselves From COVID-19
1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease As many as 40% of Covid-19 related fatalities in…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) CEO to Present at Benzinga Global Small Cap Conference
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Faz Chowdhury, Ph.D., will present at the…
-
Nemaura Medical Inc. (NASDAQ: NMRD) Offers ‘First-of-a-Kind’ Device in Growing CGM Market
The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028 The increasing prevalence of diabetes, rising focus on preventive care are significant factors in the steady revenue growth Nemaura Medical’s sugarBEAT…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2 2022 Financial, Business Report
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has reported its financial and business updates for the second quarter of FY2022,…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Extending Proprietary Technology, Programs Beyond Traditional Diabetes Market
Nemaura Medical (NASDAQ: NMRD), a cutting-edge medical technology company, recently conducted the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI-based mobile application. The…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Participation at Diabetes Technology Society Conference
Nemaura Medical (NASDAQ: NMRD)CEO Faz Chowdhury, PhD, will be presenting at annual meeting of the Diabetes Technology Society. The two-day meeting is slated for Nov. 5–6, 2021, with virtual workshops on Thursday, Nov. 4; Chowdury’s…
-
MissionIRNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Stands Distinct in Patient Support
Nemaura Medical (NASDAQ: NMRD), a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, pays close attention to essential information and research that impacts the successful implementation of its solutions.…
-
Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) Target Diabetes Tech
The world’s largest and most powerful tech companies –Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) – are targeting an opportunity in health care that’s just too big to ignore – diabetes. Almost…
Search Articles
Latest Articles
- Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy
- Soligenix Inc. (NASDAQ: SNGX) Secures Key European Milestone for Dusquetide Development
- HeartBeam Inc. (NASDAQ: BEAT) Moves Forward Focused on Advancing Portable, High-Fidelity Cardiac Monitoring
- MissionIRNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS) Announces 1-for-3 Reverse Share Split to Maintain Nasdaq Listing Compliance
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment